A SOLICITATION OF THE NATIONAL INSTITUTES OF HEALTH (NIH) AND THE CENTERS FOR DISEASE CONTROL AND PREVENTION (CDC) FOR SMALL BUSINESS INNOVATION RESEARCH (SBIR) CONTRACT PROPOSALS

1. National Institutes of Health, Bethesda, MD 20892 and Centers for Disease Control and Prevention, Atlanta, GA 30305 are soliciting proposals from small business concerns that possess the research and development (R&D) expertise to conduct innovative research that will contribute toward meeting the program objectives of the agencies. A SOLICITATION OF THE NATIONAL INSTITUTES OF HEALTH (NIH) AND THE CENTERS FOR DISEASE CONTROL AND PREVENTION (CDC) FOR SMALL BUSINESS INNOVATION RESEARCH CONTRACT PROPOSALS [PHS 2011-1], with a closing date of November 8, 2010, for receipt of proposals, soon will be available electronically through the NIH Small Business Research Funding Opportunities (http://grants.nih.gov/grants/funding/sbir.htm) Web site. The SBIR Phase I Contract Solicitation will be available ONLY via electronic means. Printed copies of the Solicitation will not be distributed. Potential offerors are encouraged to check the NIH Small Business Research Funding Opportunities Web site for updates on the program. Any updates or corrections to the Solicitation will be posted there. The purposes of the SBIR program are to: (a) stimulate technological innovation in the private sector; (b) strengthen the role of small business in meeting Federal research/research & development (R/R&D) needs; (c) increase the commercial application of Federally-supported research results; (d) foster and encourage participation by socially and economically disadvantaged small business concerns and women-owned business concerns; and improve the return on investment from Federally-funded research for economic and social benefits to the Nation. For purposes of the SBIR program, a small business concern is any business concern that, on the date of award, (1) is organized for profit, with a place of business located in the United States, which operates primarily within the United States or which makes a significant contribution to the United States economy through payment of taxes or use of American products, materials or labor; (2) is in the legal form of an individual proprietorship, partnership, limited liability company, corporation, joint venture, association, trust or cooperative, except that where the form is a joint venture, there can be no more than 49 percent participation by foreign business entities in the joint venture; (3) is at least 51 percent owned and controlled by one or more individuals who are citizens of, or permanent resident aliens in, the United States; or is owned and controlled by another (one) small business concern that is itself at least 51 percent owned and controlled by one or more individuals who are citizens of, or permanent resident aliens in, the United States; AND (4) has, including its affiliates, no more than 500 employees. Following are the research topics identified in the NIH/CDC SBIR Contract Solicitation [PHS 2011-1]: NATIONAL INSTITUTES OF HEALTH (NIH) --NATIONAL CANCER INSTITUTE (NCI): Development of Anticancer Agents; Radioprotector/Mitigator Development to Decrease Normal Tissue Injury During Radiotherapy; Development of Molecular Pharmacodynamic Assays for Targeted Therapies; Development of Devices for Point of Care Analysis of Circulating Tumor Cells; Development of Glycosylation-Specific Research Reagents (Antibodies and Aptamers); Algorithms for Automated Quantitative Imaging of Tumor Microenvironment; Systems for Automated Storage, Analysis, and Reporting of Objective Behavioral Exposures; Methods and Tools for Quantitatively Measuring Non-Coding RNAs in Cancer Early Detection, Prediction, and Diagnosis; Development of a Molecular Diagnostic Assay to Detect Basal-like Breast Cancer; Low-Field Electron Paramagnetic Resonance Imaging Device To Optimize Development Of Anti-Angiogenic Therapeutics In Cancer Animal Models (NIH Technology Transfer); A New Type of Vaccine for Prevention of HIV Infection and HIV-Associated Cancers (NIH Technology Transfer); Alternative Biospecimen Stabilization And Storage Solutions; Therapeutics and Theranostics Based on Nanotechnology; Nanotechnology Sensing Platforms for Improved Diagnosis of Cancer; Development of Clinical Automated Multiplex Affinity Capture Technology for Detecting Low Abundance Cancer-related Proteins/Peptides; Development of Quantitative Multiple Reaction Monitoring Mass Spectrometry Assays for the Detection of Cancer Related Aberrant Proteins/Peptides; Companion Diagnostics: Predictive And Prognostic Tests Enabling Personalized Medicine In Cancer Therapy; Development of Blood-based Methods for the Detection of Cancer Recurrence in Post-Therapy Breast Cancer Patients; Novel Digital X-ray Sources for Cancer Imaging Applications; Development of Innovative Algorithms/Software for Processing & Analysis of In Vivo Images in Oncology; Novel Imaging Agents to Expand the Clinical Toolkit for Cancer Diagnosis, Staging, and Treatment. NATIONAL CENTER FOR COMPLEMENTARY AND ALTERNATIVE MEDICINE (NCCAM): Develop Analytical Methodologies to Validate Label Claims for the Most Commonly Used Botanicals and Dietary Supplements; Comprehensive Biological and Phytochemical Analysis of Harpagophytum procumbens (Devil's Claw). NATIONAL CENTER FOR RESEARCH RESOURCES (NCRR): Visualizing Biomedical Research Characteristics; Equipment, Supplies and Chemical Solutions Required for High-throughput Cryopreservation of Sperm from Biomedical Model Fishes. NATIONAL HEART, LUNG AND BLOOD INSTITUTE (NHLBI): Development of Pathogen Inactivation Technologies for Blood Components; Point-of-Care Assay for Engraftment Potential of Umbilical Cord Stem Cells; Novel Technologies for Powering Ventricular Assist Devices; Informatics Tools and Services to Support Data Sharing and Distribution for Cardiovascular, Lung, and Blood Researchers; Interventional MRI and X-ray Invasive Hemodynamics Telemetry; Novel Concepts in Safe - Active Transmission Lines for MRI Catheters; Strategy for Finding Cases of Moderate-to-Severe COPD; Reagents for Studying Human Lung Cell Biology and Cellular Function. NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM (NIAAA): Interventions to Prevent and Treat Substance Abuse Among Children, Adolescents and Adults with FASD; Medications Development for the Treatment of Alcohol Use Disorders and Alcohol-Induced Tissue Damage. NATIONAL INSTITUTE ON DRUG ABUSE (NIDA): Tool Development for New or Improved Capture Reagents; Development of Alternate Drug Delivery Dosage Forms for Drugs Abuse Studies; Improving Measures of Addiction Risk; Video Game Targeting Relapse Prevention in Youth with Substance Use Disorders; Developing Implementation Packages for Evidence-based HIV Prevention Intervention Materials for Drug Users; Developing, Validating, Refining Tools for Ecologic Momentary Assessment; E-Technology Tools for Extending the Reach of Prevention Interventions in Rural and Remote Locations; Development of a Device for Auto-administering Naloxone to Overcome Overdose; Development of a Device to Assess Hyperalgesia at the Bed Side by the Cold Pressor Test; Screening, Characterization and Validation Assays for Protein Capture Reagents; Development of New Methods and Approaches to Monitor Medication Compliance in Clinical Trials; New Techniques for the Large Scale Production and Purification of Antibodies or Vaccines for the Treatment of Substance Use Disorders; Rapid Portable Devices to Measure Drug Use; Real-time Activity as a Potential Diagnostic Marker for Pain or Drug-craving; Confirming Compliance with Experimental Pharmacotherapy Treatment of Drug Abuse. NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES (NIEHS): Application of - Omics Technologies to Rodent Formalin-Fixed, Paraffin Embedded Tissue Samples; High Throughput Screening for Reactive Oxygen Species Mediating Toxicity; In Vitro 3D Tissue Models for Toxicity Testing; Development of Improved Biomarkers as Earlier Humane Endpoints for Ocular Safety Assessments; Development of Sensitive Innovative Methods for Detecting and Assessing Pain and Distress in Laboratory Animals Used in Toxicological Research and Testing. CENTERS FOR DISEASE CONTROL AND PREVENTION (CDC) - NATIONAL CENTER FOR CHRONIC DISEASE PREVENTION AND HEALTH PROMOTION (NCCDPHP): Improving Utilization of Screening Tests for Colorectal, Breast and Cervical Cancers. NATIONAL CENTER FOR HIV/AIDS, VIRAL HEPATITIS, STD, AND TB PREVENTION (NCHHSTP): Development of a Non-Invasive Method of Accurate Blood Glucose Determination. 2. NIH/CDC SBIR Contract Solicitation PHS 2011-1, including proposal forms, will be available electronically on/around August 25, 2010 through the NIH Small Business Research Funding Opportunities Web site. (Note: The PHS 2010-2 Omnibus Solicitation of the National Institutes of Health, Centers for Disease Control and Prevention, and Food and Drug Administration for Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) GRANT Applications, where investigator-initiated ideas are encouraged, is still open and is available at the same Web site noted above with remaining due dates of August 5 and December 5, 2010.) To understand better the differences between grants and contracts, see Contracts vs. Grants: What's the difference? (http://grants.nih.gov/grants/funding/contracts_vs_grants.htm) LINKURL: http://grants.nih.gov/grants/funding/sbir.htm LINKDESC: National Institutes of Health Small Business (SBIR/STTR) Research Funding Opportunities. E-mail: sbir@od.nih.gov